Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer

Inclusion Criteria

• •Patient at least 18 years old
• •Patient who read and understood the newsletter and signed the consent form
• •Renal cell carcinoma histologically proven stage IV
• •Metastatic stage proven on CT, synchronous or metachronous examination
• •Patient operated on or not from the primary tumor
• •Eligible for first-line systemic therapy with Sunitinib-targeted therapy for oncology urology
• •Affiliation to a social security scheme
• •Effective contraception (as defined by the WHO) for at least 3 months at the inclusion visit, during treatment and for 1 month after the end of the research (negative pregnancy test)
• •Postmenopausal woman: confirmatory diagnosis (amenorrhea not clinically induced for more than 12 months at inclusion visit)
• •General condition WHO 0 to 2
• •Life expectancy estimated at more than 6 months at baseline